Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma
作者:Prashant Mujumdar、Joanna Kopecka、Silvia Bua、Claudiu T. Supuran、Chiara Riganti、Sally-Ann Poulsen
DOI:10.1021/acs.jmedchem.9b00282
日期:2019.4.25
C (1), when used in combination with clinically used chemotherapeutic drugs, including temozolomide, reverses multidrug resistance and increases survival in glioblastoma, a highly aggressive primary brain tumor. We showed previously that the mechanism of action of 1 is novel, acting to indirectly interfere with P-glycoprotein drug efflux activity as a consequence of carbonic anhydrase XII (CA XII) inhibition
天然产物初级磺酰胺,psammaplin C(1)与临床使用的化疗药物(包括替莫唑胺)组合使用时,可以逆转多药耐药性并增加成胶质母细胞瘤(一种高度侵袭性原发性脑肿瘤)的存活率。我们以前表明1的作用机理是新颖的,其作用是由于碳酸酐酶XII(CA XII)抑制而间接干扰P-糖蛋白药物外排活性。为了建立构效关系,设计,合成了1的45个衍生物,并针对一组CA同工型进行了评估。化合物55被确定为CA XII的有效抑制剂(Ki = 0.56 nM),并使用胶质母细胞瘤患者的样品进行了体内和体外研究。